All
11 July 2022
String Bio, a biotech innovator, announced today that it has signed a strategic development agreement with Woodside Energy Technologies Pty Ltd, a wholly-owned subsidiary of global energy company Woodside Energy Group Ltd (Woodside).
String Bio (String) and Woodside Energy are collaborating on potential production of sustainable protein ingredients from greenhouse gases.
Woodside Energy has invested...
24 June 2022
Intento Design secures the third round of investment to accelerate its commercial deployment
Intento Design, a Paris-based french company, developing and commercializing intelligent analog design automation tools to accelerate and secure chip production, announces...
23 June 2022
Below you can find a link with presentation published by the magazine DECIDEURS about Blue Forward Fund™
Launched in December 2021 by Seventure Partners , Blue Forward Fund™ is the first European fund dedicated to blue economy...
23 June 2022
Galecto announces first patient enrolled in phase 2 trial of GB1211 in combination with Atezolizumab for first-line treatment of NSCLC
GB1211, Galecto's galectin-3 inhibitor, has shown potent anti-tumor effects and increased efficacy of checkpoint inhibition in pre-clinical models
6 June 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
6 June 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform, today announces...
2 June 2022
MaaT Pharma Confirms Positive Results from Completed Phase 1b CIMON Study Evaluating MaaT033 in Blood Cancer Patients
MaaT Pharma (EURONEXT: MAAT – the “Company”), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
24 May 2022
Dermala, a consumer dermatology company, announces their second microbiome-powered line of topical and oral products for eczema-prone skin
DERMALA, the only personalized, clinically proven treatment for acne powered by the human microbiome, extends its product range to include a second microbiome-powered line of...